Long term behavioral effects of functional dopaminergic neurons generated from human neural stem cells in the rat 6-OH-DA Parkinson's disease model. Effects of the forced expression of BCL-XL

2012 ◽  
Vol 232 (1) ◽  
pp. 225-232 ◽  
Author(s):  
Tania Ramos-Moreno ◽  
Claudia G. Castillo ◽  
Alberto Martínez-Serrano
2020 ◽  
Vol 21 (21) ◽  
pp. 8129
Author(s):  
Hyunjun Park ◽  
Keun-A Chang

Parkinson’s disease (PD) is the second most common neurodegenerative disease, which is clinically and pathologically characterized by motor dysfunction and the loss of dopaminergic neurons in the substantia nigra, respectively. PD treatment with stem cells has long been studied by researchers; however, no adequate treatment strategy has been established. The results of studies so far have suggested that stem cell transplantation can be an effective treatment for PD. However, PD is a progressively deteriorating neurodegenerative disease that requires long-term treatment, and this has been insufficiently studied. Thus, we aimed to investigate the therapeutic potential of human adipose-derived stem cells (hASC) for repeated vein transplantation over long-term in an animal model of PD. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model mice, hASCs were administered on the tail vein six times at two-week intervals. After the last injection of hASCs, motor function significantly improved. The number of dopaminergic neurons present in the nigrostriatal pathway was recovered using hASC transplantation. Moreover, the administration of hASC restored altered dopamine transporter expression and increased neurotrophic factors, such as brain-derived neurotrophic factor (BDNF) and glial cell-derived neurotrophic factor (GDNF), in the striatum. Overall, this study suggests that repeated intravenous transplantation of hASC may exert therapeutic effects on PD by restoring BDNF and GDNF expressions, protecting dopaminergic neurons, and maintaining the nigrostriatal pathway.


2006 ◽  
Vol 26 (48) ◽  
pp. 12497-12511 ◽  
Author(s):  
T. Yasuhara ◽  
N. Matsukawa ◽  
K. Hara ◽  
G. Yu ◽  
L. Xu ◽  
...  

Brain ◽  
2016 ◽  
Vol 139 (10) ◽  
pp. 2722-2739 ◽  
Author(s):  
Yong-Hee Rhee ◽  
Tae-Ho Kim ◽  
A.-Young Jo ◽  
Mi-Yoon Chang ◽  
Chang-Hwan Park ◽  
...  

Theranostics ◽  
2018 ◽  
Vol 8 (17) ◽  
pp. 4679-4694 ◽  
Author(s):  
Yanpeng Yuan ◽  
Xihe Tang ◽  
Yun-Fei Bai ◽  
Shuyan Wang ◽  
Jing An ◽  
...  

2008 ◽  
Vol 211 (2) ◽  
pp. 362-369 ◽  
Author(s):  
Kimberly B. Bjugstad ◽  
Yang D. Teng ◽  
D. Eugene Redmond ◽  
John D. Elsworth ◽  
Robert H. Roth ◽  
...  

Author(s):  
Meng Cai ◽  
Songshan Chai ◽  
Tao Xiong ◽  
Jun Wei ◽  
Weibing Mao ◽  
...  

A group of circulating microRNAs (miRNAs) have been implicated in the pathogenesis of Parkinson’s disease. However, a comprehensive study of the interactions between pathogenic miRNAs and their downstream Parkinson’s disease (PD)-related target genes has not been performed. Here, we identified the miRNA expression profiles in the plasma and circulating exosomes of Parkinson’s disease patients using next-generation RNA sequencing. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses showed that the miRNA target genes were enriched in axon guidance, neurotrophin signaling, cellular senescence, and the Transforming growth factor-β (TGF-β), mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT) and mechanistic target of rapamycin (mTOR) signaling pathways. Furthermore, a group of aberrantly expressed miRNAs were selected and further validated in individual patient plasma, human neural stem cells (NSCs) and a rat model of PD. More importantly, the full scope of the regulatory network between these miRNAs and their PD-related gene targets in human neural stem cells was examined, and the findings revealed a similar but still varied downstream regulatory cascade involving many known PD-associated genes. Additionally, miR-23b-3p was identified as a novel direct regulator of alpha-synuclein, which is possibly the key component in PD. Our current study, for the first time, provides a glimpse into the regulatory network of pathogenic miRNAs and their PD-related gene targets in PD. Moreover, these PD-associated miRNAs may serve as biomarkers and novel therapeutic targets for PD.


2007 ◽  
Vol 57 (3) ◽  
pp. 393-398 ◽  
Author(s):  
Hideki Hayakawa ◽  
Hiromi Hayashita-Kinoh ◽  
Tomoko Nihira ◽  
Tatsunori Seki ◽  
Yoshikuni Mizuno ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document